$4.10
+0.10 (+2.50%)
Open$4.09
Previous Close$4.00
Day High$4.11
Day Low$4.09
52W High$18.40
52W Low$3.24
Volume—
Avg Volume10.4K
Market Cap40.84M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 13.14M | 13.93M | 11.00M |
| Net Income | -2,417,675 | -2,785,079 | -2,350,186 |
| Profit Margin | -18.4% | -20.0% | -21.4% |
| EBITDA | -3,490,436 | -4,206,535 | -3,083,781 |
| Free Cash Flow | -1,263,655 | -1,934,401 | -1,577,892 |
| Rev Growth | -4.0% | +11.1% | -5.6% |
| Debt/Equity | 0.43 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |